PT885904E - Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme - Google Patents

Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme

Info

Publication number
PT885904E
PT885904E PT98110629T PT98110629T PT885904E PT 885904 E PT885904 E PT 885904E PT 98110629 T PT98110629 T PT 98110629T PT 98110629 T PT98110629 T PT 98110629T PT 885904 E PT885904 E PT 885904E
Authority
PT
Portugal
Prior art keywords
amiloid
cytotoxicity
agonists
alzheimer
peptides
Prior art date
Application number
PT98110629T
Other languages
English (en)
Inventor
Jurgen Bernhagen
Afroditi Kapurnioutu
Herwig Brunner
Original Assignee
Fraunhofer G Foerderung Angewa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer G Foerderung Angewa filed Critical Fraunhofer G Foerderung Angewa
Publication of PT885904E publication Critical patent/PT885904E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT98110629T 1997-06-17 1998-06-10 Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme PT885904E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19725619A DE19725619A1 (de) 1997-06-17 1997-06-17 Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien

Publications (1)

Publication Number Publication Date
PT885904E true PT885904E (pt) 2004-08-31

Family

ID=7832754

Family Applications (1)

Application Number Title Priority Date Filing Date
PT98110629T PT885904E (pt) 1997-06-17 1998-06-10 Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme

Country Status (9)

Country Link
US (1) US6359112B2 (pt)
EP (1) EP0885904B1 (pt)
JP (1) JPH1171393A (pt)
AT (1) ATE262540T1 (pt)
CA (1) CA2240005A1 (pt)
DE (2) DE19725619A1 (pt)
DK (1) DK0885904T3 (pt)
ES (1) ES2221965T3 (pt)
PT (1) PT885904E (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19909357A1 (de) * 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE19916417A1 (de) * 1999-04-01 2000-10-19 Schering Ag Amyloidspezifisches Aptamer
GB9917724D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
GB9917725D0 (en) 1999-07-28 1999-09-29 Medical Res Council Peptides
AU4183200A (en) * 1999-10-21 2001-04-30 Panorama Research, Inc. A general method for optimizing the expression of heterologous proteins
EP1325028A2 (en) 2000-09-19 2003-07-09 University Of Toronto New inhibitors of iapp fibril formation and uses thereof
DE10101430B4 (de) 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US7884067B2 (en) * 2001-10-05 2011-02-08 Mount Sinai School Of Medicine Of New York University Peptides derived from cadherin and methods of use thereof
CA2466841A1 (en) * 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004060791A1 (en) 2003-01-07 2004-07-22 Ramot At Tel Aviv University Ltd. Peptide nanostructures encapsulating a foreign material and method of manufacturing same
EP1603944A1 (en) * 2003-03-18 2005-12-14 Applied Research Systems ARS Holding N.V. Amylin aggregation inhibitors and use thereof
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
JP4917889B2 (ja) 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
US7625707B2 (en) 2003-10-02 2009-12-01 Ramot At Tel Aviv University Ltd. Antibacterial agents and methods of identifying and utilizing same
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
WO2005079830A1 (en) * 2004-02-23 2005-09-01 Paul Fraser Inhibitors of amyloid fibril formation and uses thereof
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
US20090156471A1 (en) * 2004-07-15 2009-06-18 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
WO2006018850A2 (en) 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
US7786086B2 (en) * 2004-09-08 2010-08-31 Ramot At Tel-Aviv University Ltd. Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
JP2008527563A (ja) 2005-01-16 2008-07-24 ズランゴー リミテッド アイコニック通信
US20100152418A1 (en) * 2005-06-17 2010-06-17 Epfl Ecole Polytechnique Federale De Lausanne Switch-Peptides as Tool for the Study of Fibrillogenesis
WO2007043048A2 (en) 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US7879212B2 (en) 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
US20100163221A1 (en) * 2005-11-30 2010-07-01 Koninklijke Philips Electronics, N.V. Local control of heat flow to more accurately regulate machine temperatures
EP1982450A2 (en) 2006-01-16 2008-10-22 Zlango Ltd. Communications network system and methods for using same
EP1977312A2 (en) 2006-01-16 2008-10-08 Zlango Ltd. Iconic communication
BR112013012033A2 (pt) 2010-11-15 2016-08-09 Merz Pharma Gmbh & Co Kgaa análogos de dipeptídeos para o tratamento de condições associadas com a formação de fibrila amiloide
US9814761B2 (en) 2012-04-03 2017-11-14 Trustees Of Boston University Compositions, methods and assays comprising amylin or amlyin analogs for abeta-peptide mediated disorders
CU20130027A7 (es) 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CN112279889B (zh) * 2020-10-27 2022-12-06 泰州学院 一种多肽、衍生物及其在制备抗肿瘤药物方面的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709871D0 (en) * 1987-04-27 1987-06-03 Turner R C Peptides
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
JP4233604B2 (ja) * 1991-12-03 2009-03-04 プロセリックス メディスンズ ディベロップメント リミテッド プリオンタンパク質のフラグメント
US5514653A (en) * 1994-09-09 1996-05-07 Washington University Method of blocking the SEC receptor
JPH11514333A (ja) * 1995-03-14 1999-12-07 プレーシス ファーマスーティカルズ インコーポレイテッド アミロイドの凝集の調節剤
US5948763A (en) * 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits

Also Published As

Publication number Publication date
DE19725619A1 (de) 1998-12-24
ATE262540T1 (de) 2004-04-15
CA2240005A1 (en) 1998-12-17
JPH1171393A (ja) 1999-03-16
EP0885904A1 (de) 1998-12-23
US6359112B2 (en) 2002-03-19
DK0885904T3 (da) 2004-07-05
US20010007015A1 (en) 2001-07-05
ES2221965T3 (es) 2005-01-16
DE59811036D1 (de) 2004-04-29
EP0885904B1 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
PT885904E (pt) Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme
CA2270289A1 (en) Proteins with enhanced levels of essential amino acids
ATE399177T1 (de) Derivate therapeutischer peptide
ATE368053T1 (de) Antimikrobielle peptide
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
BR9407583A (pt) Processos para produzir uma proteina bcl-2 mutante para identificar agentes modulantes de bcl-2 candidatos um bcl-2 mutante e proteinas bcl-2 mutantes e para inibir a atividade repressora de morte de células de bcl-2 e polipeptideo bcl-2 mutante
NO942553D0 (no) Ny humanproteaseinhibitor av Kunitz-type og varianter derav
SE0002202D0 (sv) New peptides
AR015498A1 (es) Composiciones de edulcorante de mesa.
ATE257859T1 (de) Humanes, rekombinantes interferon-beta mit verbesserter löslichkeit
ATE278708T1 (de) Conotoxin peptid pviia
NO960939D0 (no) Kininogenaseinhibitor
NO302472B1 (no) Sulfonylureaforbindelse, farmasöytisk formulering og anvendelse derav
ES2168282T3 (es) D-hidantoinasa recombinante, procedimiento para su preparacion y utilizacion.
DK1012175T3 (da) Peptid med affinitet til koagulationsfaktor VIII
ES2151970T3 (es) Peptidos dotados de actividad anti-inflamatoria.
ATE170873T1 (de) Bombesin-analogen
DE60038310D1 (de) Menschliche antithrombin-varianten
AR247473A1 (es) Una composicion que produce una respuesta lactogenica o crecimiento en ganado bovino, excluidas todas sus aplicaciones terapeuticas
Kongsrud et al. Characterization of amyloid fibril proteins in masses of amyloid located to the nasal conchae of a horse
DE68915988D1 (de) Rekombinante Polypeptide des hämorrhagischen Fisch-Sepsis-Virus.
AR004485A1 (es) Insulina de cadena sencilla con alta bioactividad
ECSP961741A (es) Insulina de caneda sencilla con alta bioactividad (
ECSP003457A (es) Derivados de proteina c